ALMS · Alumis Inc.
$7.24
+0.27 (+3.87%)
At close · Oct 9
Return incl. dividend (before tax)
Market Cap
$876.28M
Shares
129.44M
Volume · Oct 8
2.85M
Avg daily vol (3M)
2.44M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.97
Open$6.66
Day$6.61–7.02
52W close$4.43–30.30
Avg vol 30d4.1M
Short int6.3M · 4.9% float · 1.0d
Short vol28%
Last earningsSep 1, 2026
DataJun 2024–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Oct 26, 2026
Est · unconfirmed
· in 2 wks
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$7.40M
Trailing 12 months
Net income (TTM)
−$438.96M
Trailing 12 months
Revenue growth YoY
-37.7%
Year over year
Operating margin
-6,204.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-40.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+66.6%
Year over year · more shares
Price change (1Y)
+50.1%
Trailing year
Short interest
4.9%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−68%
below
Price vs 50-day avg
−57%
below
RSI (14)
24
oversold
MACD trend
Positive
52-week position
10%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−30%
trailing
6-month return
−72%
trailing
YTD return
−29%
this year
Relative strength
−81%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $16 › 200d $22 — 200d above 50d
Institutional flow
Accumulating
5 of 203 funds reported for Sep 30 · net +181 sh shares
Insider flow
Accumulating
Net +$9.3M over 90 days · 88% sells
Short interest
Rising
4.87% of float · ▲ +11.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
203 holders — near 2-yr high, broad support
Squeeze score
43
elevated · 0–100
Fundamentals
EPS growth
+72%
Y/Y
Free cash flow
$-370.2M
Quant / Vol
risk profile
Volatility
136%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
10.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−68%
Bearish
Price vs 50-day avg
−57%
Bearish
RSI (14)
24
Neutral
MACD trend
Positive
Bullish
52-week position
10%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $16 › 200d $22 — 200d above 50d
Institutional flow
Accumulating
5 of 203 funds reported for Sep 30 · net +181 sh shares
Insider flow
Accumulating
Net +$9.3M over 90 days · 88% sells
Short interest
Rising
4.87% of float · ▲ +11.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
203 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $7 · 10%
Range high $30
vs 200-day avg -68%
vs 50-day avg -57%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALMS
this stock
Alumis Inc.
|
$876.28M | -28.6% | — | — | 4.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.16B | +11.0% | +46.2% | 29.5 | 1.9% |
|
MRNA
Moderna, Inc.
|
$78.65B | +568.0% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.14B | -4.2% | +20.8% | 18.3 | 2.5% |
|
CSLLY
Csl Ltd
|
$60.24B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALMS | -3.3% | -29.6% | -72.1% | -5.7% | -28.6% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | -4.6% | -31.7% | -81.1% | -7.2% | -42.1% |